<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737785</url>
  </required_header>
  <id_info>
    <org_study_id>8414(0)136</org_study_id>
    <nct_id>NCT04737785</nct_id>
  </id_info>
  <brief_title>Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation: a Prospective Observational Trial From the Infectious Diseases Working Party and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Society for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients undergoing allogeneic or autologous HSCT at the participating centres will be&#xD;
      observed. Once a diagnosis of CNS disorder is made, additional data will be reported for&#xD;
      these patients.&#xD;
&#xD;
      We will identify clinical and diagnostic characteristics such as cerebrospinal fluid (CSF)&#xD;
      and neuroimaging patterns, risk factors, response to treatment (including novel antifungal&#xD;
      agents such as isavuconazole) and outcome. In addition, risk factors for CNS disorders after&#xD;
      allogeneic and autologous HSCT will be analyzed using a prospectively assessed matched&#xD;
      control group. In the future, this study might be the basis for an interventional trial (e.g.&#xD;
      using a prophylactic approach).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For each case patient (i.e. HSCT recipient with a CNS disorder) two control patients (1:2&#xD;
      allocation) should be analysed prospectively with the aim to get more insights into risk&#xD;
      factors for CNS disorders. Hereby, the two patients transplanted subsequently to the&#xD;
      corresponding case patient should be included as controls if they survive and do not develop&#xD;
      a CNS disorder until the inclusion time point. Inclusion time points of controls should be&#xD;
      determined by using the same delay between transplant and the onset of the CNS disorder of&#xD;
      the corresponding case patient. Controls should also be stratified by centre, HSCT type (i.e.&#xD;
      allogeneic vs. autologous) and age (adults vs. paediatrics). As for cases with CNS disorders,&#xD;
      controls should also be evaluated regularly until last follow-up. To avoid bias and to&#xD;
      estimate the incidence of infectious vs. non-infectious CNS disorders in autologous and&#xD;
      allogeneic HSCT recipients accurately centres should also report patients with CNS disorders&#xD;
      not included in this study (e.g. due to lack of informed consent or essential Med-A data).&#xD;
      Centres are additionally asked by the data management office in Leiden/Netherlands for these&#xD;
      data on a regularly basis.&#xD;
&#xD;
      Primary objectives&#xD;
&#xD;
        -  Clinical and diagnostic characteristics of infectious and non-infectious CNS disorders&#xD;
           following allogeneic or autologous HSCT&#xD;
&#xD;
        -  Outcome 30 days after CNS disorder onset (cured vs. improved vs. stabilized vs. worsened&#xD;
           vs. died due to CNS disorder vs. died by other cause)&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  Incidence, timing, and distribution of infectious and non-infectious CNS disorders after&#xD;
           HSCT&#xD;
&#xD;
        -  Impact of development of CNS disorders on overall survival&#xD;
&#xD;
        -  Risk factors for CNS disorders after allogeneic and autologous HSCT using a&#xD;
           prospectively assessed matched control group&#xD;
&#xD;
        -  Efficacy of treatment for different types of CNS disorders&#xD;
&#xD;
      Data Collection &amp; Statistical Analysis Plan Data collection will be performed by the IDWP&#xD;
      data office (Leiden/Netherlands). Hereby, patient and transplant data are reported directly&#xD;
      from the centres to the data office according to EBMT guidelines.&#xD;
&#xD;
      Important basic data for analysis (collected from Med-A and Med-C for both case patients and&#xD;
      controls):&#xD;
&#xD;
        -  Recipient/donor sex&#xD;
&#xD;
        -  Recipient/donor age (at HSCT)&#xD;
&#xD;
        -  Primary diagnosis (leading to HSCT)&#xD;
&#xD;
        -  Status of the primary disease at the time of HSCT - remission (partial or&#xD;
           complete)/relapse/relapse including CNS involvement/progression, stable disease,&#xD;
           unknown)&#xD;
&#xD;
        -  Prior CNS radiotherapy&#xD;
&#xD;
        -  Prior intrathecal (antineoplastic) treatment&#xD;
&#xD;
        -  Prior (antineoplastic) treatment (especially 'novel drugs´)&#xD;
&#xD;
        -  Pre-existing medical conditions, e.g. chronic kidney disease, liver disease&#xD;
&#xD;
        -  Recipient/donor serostatus of CMV, EBV, HHV-6, HSV, VZV, Toxoplasma spp.&#xD;
&#xD;
        -  Type of transplant (allogeneic vs. autologous)&#xD;
&#xD;
        -  Type of donor (MRD vs. haploidentical donor vs. other donor type)&#xD;
&#xD;
        -  Stem cell source (CB vs. BM vs. PB)&#xD;
&#xD;
        -  Type of conditioning (e.g. MAC vs. RIC, fludarabine-containing vs. other, TBI incl.&#xD;
           dose), including details on absolute dose and dose adjustments of fludarabine&#xD;
&#xD;
        -  TCD (yes vs. no), ATG (yes vs. no), alemtuzumab (yes vs. no) in conditioning and at&#xD;
           study inclusion (day 0)&#xD;
&#xD;
        -  Acute and chronic GvHD (at day 0, including grade)&#xD;
&#xD;
        -  ECOG performance status at different time points&#xD;
&#xD;
        -  Concomitant infections: e.g. paranasal sinusitis, results of blood cultures performed&#xD;
           during the episode of CNS disorder, galactomannan, beta-D-glucan (peripheral blood, BAL&#xD;
           etc.)&#xD;
&#xD;
        -  Selected peripheral blood parameters, e.g. white blood cell count, absolute neutrophil&#xD;
           count, duration of neutropenia &lt;0.5x109/L, absolute lymphocyte count, platelet count,&#xD;
           sodium, potassium, calcium, phosphate, creatinine, urea nitrogen, ammonia, bilirubin,&#xD;
           IgG concentration, creatinine, GFR&#xD;
&#xD;
      Specific data to be collected for patients with CNS disorders (see also Med-C for cases and&#xD;
      appendix), e.g.:&#xD;
&#xD;
        -  Recipient´s age at onset of the CNS disorder (day 0)&#xD;
&#xD;
        -  Date of symptom onset of the CNS disorder&#xD;
&#xD;
        -  Type of symptoms (e.g. seizures, hemiplegia, paraplegia, paresis, psychosis, vomiting,&#xD;
           confusion/altered consciousness, fever)&#xD;
&#xD;
        -  Date of diagnosis of the CNS disorder (e.g. CSF analysis)&#xD;
&#xD;
        -  Clinical diagnosis of CNS infection (e.g. encephalitis, meningitis, meningoencephalitis,&#xD;
           myelitis, abscess, leukoencephalopathy)&#xD;
&#xD;
        -  Clinical diagnosis of non-infectious CNS disorder (e.g. metabolic/drug-induced disorder,&#xD;
           posterior reversible encephalopathy syndrome, bleeding, thrombosis, ischemic stroke, CNS&#xD;
           relapse of a underlying malignancy)&#xD;
&#xD;
        -  Time interval between HSCT and symptom onset&#xD;
&#xD;
        -  Time interval between symptom onset and diagnosis of CNS disorder&#xD;
&#xD;
        -  Antimicrobial prophylaxis prior to onset of a CNS disorder&#xD;
&#xD;
        -  Level of likelihood of the type of CNS disorder - the centres report the diagnostic&#xD;
           tests performed to make a diagnosis of CNS disorder including i.e.: magnetic resonance&#xD;
           imaging (MRI), MRI spectrometry, positron emission tomography/computed tomography&#xD;
           (PET/CT), CT, electroencephalography (EEG), CSF analyses, microbiological studies (e.g.,&#xD;
           cultures, PCR, galactomannan, Candida mannan, beta-D-glucan, antibodies in peripheral&#xD;
           blood, CSF or other materials such as brain biopsy), autopsy results&#xD;
&#xD;
        -  Type and efficacy of treatment for the CNS disorder 30 days after onset (cured vs.&#xD;
           improved vs. stabilized vs. worsened vs. died due to CNS disorder vs. died by other&#xD;
           cause)&#xD;
&#xD;
        -  Outcome (alive or death, including date, cause of death, CNS disorder-related death vs.&#xD;
           other death cause) at the different study points&#xD;
&#xD;
      Specific data to be collected for patients without CNS disorder (see also Med-C for&#xD;
      controls), e.g.:&#xD;
&#xD;
        -  Time interval between HSCT and day 0 (inclusion time point, same delay between&#xD;
           transplant and CNS disorder onset of the corresponding case)&#xD;
&#xD;
        -  Date of study inclusion (i.e. day 0)&#xD;
&#xD;
        -  Recipient´s age at study inclusion&#xD;
&#xD;
        -  Occurrence of a CNS disorder after study inclusion&#xD;
&#xD;
        -  Antimicrobial prophylaxis prior to study inclusion&#xD;
&#xD;
        -  Outcome (alive or death, including date, cause of death) at the different study points&#xD;
&#xD;
      Statistical analysis Statistical methods used to compare groups for primary and secondary&#xD;
      outcomes Primary endpoints: descriptive statistics will be performed to report the main&#xD;
      characteristics (and 30 day outcome) of patients with infectious and non-infectious CNS&#xD;
      disorders: absolute and percentage frequencies will be reported for categorical variables;&#xD;
      median, IQR and range will be used for continuous variables.&#xD;
&#xD;
      Secondary endpoints: the cumulative incidence of infectious and non-infectious CNS disorders&#xD;
      after HSCT will be estimated by the cumulative incidence method: infectious and&#xD;
      non-infectious CNS disorders will be considered as events, whilst non-CNS relapse, non-CNS&#xD;
      secondary malignancy and non-CNS death will be considered as competing event. Overall&#xD;
      survival will be assessed using Kaplan-Meier curves, and the impact of the development of CNS&#xD;
      disorders on overall survival will be assessed using time-dependent Cox models. To compute&#xD;
      these endpoints, the data of all patients after HSCT will be obtained from the EBMT patient&#xD;
      databases (e.g. ProMISe).&#xD;
&#xD;
      The risk factor analysis will be performed by a conditional logistic regression model.&#xD;
      P-values &lt;0.05 will be considered statistically significant. The analyses will be performed&#xD;
      using the software SAS/R v 9.4 or higher (SAS Institute Inc., Cary, NC, USA).&#xD;
&#xD;
      Methods for additional analyses, such as subgroup analyses and adjusted analyses The&#xD;
      cumulative incidence of infectious and non-infectious CNS disorders after HSCT will be&#xD;
      computed and reported separately for different transplant types (autologous vs. allogeneic -&#xD;
      matched related donor vs. haploidentical donor vs. other donor type), and stem cell source&#xD;
      (cord blood vs. bone marrow vs. peripheral blood) of HSCT and for different age categories&#xD;
      (adults vs. paediatrics). These comparisons will be presented in terms of crude cumulative&#xD;
      incidence curves, and differences between groups will be assessed using Gray's test.&#xD;
      Multivariable analyses will be performed using cause-specific hazard models. Cox models for&#xD;
      overall survival will include CNS disorders as time-dependent covariates. Candidate variables&#xD;
      for these analyses will be obtained from a list of predefined variables, including (but not&#xD;
      limited to) type of transplant (allogeneic vs. autologous HSCT), age, stem cell source, donor&#xD;
      relationship, and use of T cell depletion. Potential effects of centres will be examined&#xD;
      using random effects.&#xD;
&#xD;
      Risk factors for CNS disorders after allogeneic and autologous HSCT will be assessed using&#xD;
      multivariable conditional logistic regression. Candidate variables for this analysis will be&#xD;
      obtained from a list of predefined variables, including the stratification variables.&#xD;
&#xD;
      Model building will proceed as follows: each variable will be preliminarily assessed using&#xD;
      univariable analyses. Factors associated with the response and significant at the 20% level&#xD;
      in univariable analyses will be considered for inclusion in a multivariable model. Factors&#xD;
      will be retained if significant at the 5% level, and interaction terms included (after&#xD;
      assessment of main effects) if significant at a 10% level (with possible corresponding&#xD;
      subgroup analyses used to illustrate differential effects).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Clinical characteristics of infectious and non-infectious CNS disorders following allogeneic or autologous HSCT</measure>
    <time_frame>32 months</time_frame>
    <description>Clinical characteristics to be analysed:&#xD;
Recipient/donor sex&#xD;
Recipient/donor age (at HSCT)&#xD;
Primary diagnosis&#xD;
Status of the primary disease at the time of HSCT - remission (partial or complete) /relapse /relapse including CNS involvement/progression, stable disease, unknown)&#xD;
Prior CNS radiotherapy&#xD;
Prior intrathecal (antineoplastic) treatment&#xD;
Prior (antineoplastic) treatment (especially 'novel drugs´)&#xD;
Pre-existing medical conditions&#xD;
Recipient/donor serostatus of CMV, EBV, HHV-6, HSV, VZV, Toxoplasma spp.&#xD;
Type of transplant (allogeneic vs. autologous)&#xD;
Type of donor (MRD vs. haploidentical donor vs. other donor type)&#xD;
Stem cell source (CB vs. BM vs. PB)&#xD;
Type of conditioning (RIC vs MAC)&#xD;
TCD (yes vs. no), ATG (yes vs. no), alemtuzumab (yes vs. no)&#xD;
Acute and chronic GvHD (at day 0, including grade)&#xD;
ECOG performance status at different time points&#xD;
Concomitant infections&#xD;
Selected peripheral blood parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic characteristics of infectious and non-infectious CNS disorders following allogeneic or autologous HSCT</measure>
    <time_frame>32 months</time_frame>
    <description>Diagnostic characteristics analyzed:&#xD;
Recipient´s age at onset of the CNS disorder (day 0)&#xD;
Date of symptom onset of the CNS disorder&#xD;
Type of symptoms (e.g. seizures, hemiplegia, paraplegia, paresis, psychosis, vomiting, confusion/altered consciousness, fever)&#xD;
Date of diagnosis of the CNS disorder (e.g. CSF analysis)&#xD;
Clinical diagnosis of CNS infection (e.g. encephalitis, meningitis, meningoencephalitis, myelitis, abscess, leukoencephalopathy)&#xD;
Clinical diagnosis of non-infectious CNS disorder (e.g. metabolic/drug-induced disorder, posterior reversible encephalopathy syndrome, bleeding, thrombosis, ischemic stroke, CNS relapse of a underlying malignancy)&#xD;
Time interval between HSCT and symptom onset&#xD;
Time interval between symptom onset and diagnosis&#xD;
Antimicrobial prophylaxis prior to onset of CNS disorder&#xD;
Level of likelihood of the type of CNS disorder:</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of CNS treatment for different types of CNS disorders</measure>
    <time_frame>30 days</time_frame>
    <description>Efficacy measured as:&#xD;
CNS cured with neurological sequelae&#xD;
CNS cured without neurological sequelae&#xD;
CNS symptoms improved&#xD;
CNS symptoms stabilized&#xD;
deteriorating&#xD;
death because of CNS disorder&#xD;
death because of other cause&#xD;
Treatments analyzed:&#xD;
Antimicrobials&#xD;
Steroids&#xD;
Surgical treatment&#xD;
Reduction of immunosuppression&#xD;
Other treatment&#xD;
Types of CNS disorders:&#xD;
infectious&#xD;
non-infectious</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>32 months</time_frame>
    <description>alive or death, including date, cause of death, CNS disorder-related death vs. other death cause at the different study points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious and non-infectious CNS disorders after HSCT</measure>
    <time_frame>32 months</time_frame>
    <description>To identify the Incidence of infectious and non-infectious CNS disorders after HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing of infectious and non-infectious CNS disorders after HSCT</measure>
    <time_frame>32 months</time_frame>
    <description>To identify the timing of infectious and non-infectious CNS disorders after HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of infectious and non-infectious CNS disorders after HSCT</measure>
    <time_frame>32 months</time_frame>
    <description>To identify the distribution of infectious and non-infectious CNS disorders after HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of development of CNS disorders on overall survival</measure>
    <time_frame>32 months</time_frame>
    <description>to identify the Impact of development of CNS disorders (yes/no) on overall survival (alive/dead) using a prospectively assessed matched control group without CNS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for CNS disorders after allogeneic and autologous HSCT using a prospectively assessed matched control group</measure>
    <time_frame>32 months</time_frame>
    <description>Risk factors assed:&#xD;
Recipient/donor sex&#xD;
Recipient/donor age (at HSCT)&#xD;
Primary diagnosis&#xD;
Status of the primary disease at the time of HSCT&#xD;
Prior CNS radiotherapy&#xD;
Prior intrathecal (antineoplastic) treatment&#xD;
Prior (antineoplastic) treatment (especially 'novel drugs´)&#xD;
Pre-existing medical conditions&#xD;
Recipient/donor serostatus of CMV, EBV, HHV-6, HSV, VZV, Toxoplasma spp.&#xD;
Type of transplant (allogeneic vs. autologous)&#xD;
Type of donor (MRD vs. haploidentical donor vs. other donor type)&#xD;
Stem cell source (CB vs. BM vs. PB)&#xD;
Type of conditioning (RIC vs MAC)&#xD;
TCD (yes vs. no), ATG (yes vs. no), alemtuzumab (yes vs. no)&#xD;
Acute and chronic GvHD (at day 0, including grade)&#xD;
ECOG performance status at different time points&#xD;
Concomitant infections&#xD;
Selected peripheral blood parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment for different types of CNS disorders</measure>
    <time_frame>32 months</time_frame>
    <description>Efficacy of treatment measured as:&#xD;
CNS cured with neurological sequelae&#xD;
CNS cured without neurological sequelae&#xD;
CNS symptoms improved&#xD;
CNS symptoms stabilized&#xD;
deteriorating&#xD;
death because of CNS disorder&#xD;
death because of other cause</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Central Nervous System Infections</condition>
  <condition>Central Nervous System Complication</condition>
  <condition>Infectious Disease of Nervous System</condition>
  <condition>Blood Disease</condition>
  <condition>Blood Cancer</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <description>HSCT recipients who developed a CNS disorder after HSCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>HSCT recipients whom did not develop a CNS disorder</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HSCT patients of any age with any underlying disease for which the transplant is given.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Case group:&#xD;
&#xD;
          -  received allogeneic or autologous HSCT between January 1st, 2021 and December 31st,&#xD;
             2022&#xD;
&#xD;
          -  develop an infectious (any CTCAE grade) or relevant (CTCAE &gt;1°) non-infectious CNS&#xD;
             disorder after HSCT in this period.&#xD;
&#xD;
        Control group:&#xD;
&#xD;
          -  received allogeneic or autologous HSCT between January 1st, 2021 and February 28th,&#xD;
             2023&#xD;
&#xD;
          -  who survive and do not develop a CNS disorder until the inclusion time point (day 0,&#xD;
             defined as the same delay between transplantation and CNS disorder onset of the&#xD;
             corresponding case)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with missing essential Med-A data&#xD;
&#xD;
          -  Patients not giving informed consent to report data to EBMT prior to initiation of&#xD;
             transplant procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schmidt-Hieber, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carl-Thiem-Klinikum, Clinic for Hematology and Oncology, Cottbus, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Knelange</last_name>
    <phone>+31 (0) 71 526 1513</phone>
    <email>idwpebmt@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Knelange, MSc</last_name>
    <email>s.b.m.knelange@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Mistry</last_name>
      <email>Mayuriben.Mistry@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital St. Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alienor Xhaard, Dr</last_name>
      <email>alienor.xhaard@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum</name>
      <address>
        <city>Cottbus</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schmidt-Hieber</last_name>
      <email>M.Schmidt_Hieber@ctk.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Southern Pest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Csaba</last_name>
      <email>kassa.csaba@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute G. Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura Faraci, Dr</last_name>
      <email>maurafaraci@gaslini.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Mainardi</last_name>
      <email>chiara.mainardi@aopd.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica S. Cuore</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Metafuni</last_name>
      <email>bettymetafuni@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital, Collegium Medicum UMK</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Czyzewski</last_name>
      <email>k.czyzewski@cm.umk.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital in Krakow</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Gozdzik</last_name>
      <email>jgozdzik@cm-uj.krakow.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raisa Gorbacheva Research Institute for Oncology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Polushin, MD</last_name>
      <email>alexpolushin@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Martino</last_name>
      <email>RMartino@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria ms Calbacho Robles</last_name>
      <email>mcalbachorobles@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niño Jesus Children's Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M gonzalez vicent</last_name>
      <email>martagonzalezvicent@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Rosello</last_name>
      <email>aitabalag@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Ntl de greffe de MO de Tunis</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N Abdejlil</last_name>
      <email>nour.abdejlil@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Central Nervous System Infections</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

